Arthrosamid® is a non-biodegradable hydrogel composed of 2.5% crosslinked Polyacrylamide and 97.5% water, 2.5% IPAAG. It is registered as an injectable implant because it forms a permanent part of the knee joint and provides long-term pain relief – improving the quality of life of patients with knee osteoarthritis
Arthrosamid® is safe, biocompatible, non-resorbable and non-degradable. After injection into the synovial joint cavity, Arthrosamid fuses with the synovial tissue and remains there and does not degrade.
This hydrogel has been used for 25 years and more than 1,800,000 patients have been treated with it for various conditions. There are no known long-term side reactions.
After Arthrosamid treatment, it is possible to place a knee replacement with no known side effects related to Arthrosamid treatment.
Clinical studies show that after approximately 6 weeks to 4 months after injection, patients experience a marked reduction in pain and have improved mobility and functionality for up to 5 years after treatment. These results are seen in 80% of cases.
There is a difference between treatment effect and patient age. In young patients, under 60 years the probability of a positive effect is 95%. In Patients over 70 years this effect 63%. Among patients who are positive, the vast majority are still positive after 5 years.
Research after 10 years has shown that 56% of patients with osteoarthritis still have not had knee replacement surgery.
Arthrosamid® is injected into the joint crevice of the knee and provides a natural barrier to the inflammatory cells, makes the inner lining more elastic and causes the body to produce better joint fluid again, allowing the patient to experience fewer symptoms and function better.
It is recommended that a prophylactic antibiotic be administered orally prior to surgery (because it is listed in the package insert) and the injection should be considered an implant.
For the patient’s well-being, it is advisable to give a local anesthetic in the skin and in the joint in the form of, for example, lidocaine prior to the injections.
Several studies show the positive effect of Arthrosamid over a period of several years. The 5-year results have been presented from the IDA study. Those of the Rosa study are expected by the end of 2025. It can be seen that patients who respond positively after 5 years show a similar response than in year one.
